Ingredion (INGR) Q2 2026 Earnings Call Transcript
Ingredion (INGR) reported Q2 2026 net sales of $1.85 billion (+1%) and adjusted operating income of $258 million (-5%). Adjusted EPS was $2.82. Results reflected volume growth in Texture & Healthful Solutions, but currency headwinds in Mexico and Argo facility issues. Full-year 2026 adjusted EPS guidance is $10.30 to $10.90; cash from ops $700m to $800m. Tate & Lyle acquisition pending.
How this was made
The 30-second read
Why it matters
Key decision inputs are the updated 2026 operating income down mid-single digits, cash from operations guidance adjusted for Pakistan divestiture, and deal targets (synergies run-rate by 2030, >15% EPS accretion in first full calendar year after close, net leverage <2.5x within 18 months). Operationally, U.S./Canada income is down 33% year over year due to Argo headwinds, while tapioca root costs are up more than 40% with a 1 to 1.5 quarter pass-through lag.
Market read
This call provides fresh, tradable guidance and deal metrics plus quantified margin and cost headwinds, which can drive near-term positioning around 2026 earnings trajectory and acquisition integration expectations.
What to watch
The guidance shift is driven by the Pakistan divestiture and Argo reliability spending; traders may underweight how reliability capex and production normalization affect second-half earnings quality.
Background
Ingredion’s Q2 2026 earnings call covers segment performance, Argo facility recovery, raw-material cost inflation, and progress on the pending Tate & Lyle acquisition plus the Pakistan business divestiture.
Ticker impact
Ingredion reported Q2 results and reaffirmed 2026 adjusted EPS guidance while updating operating income and cash flow expectations tied to the Pakistan divestiture and Tate & Lyle deal.
Moderate volatility likely as investors weigh Argo recovery and cost pass-through timing against reaffirmed EPS guidance and the Tate & Lyle accretion/leverage targets.
The article contains multiple concrete, decision-relevant datapoints: Q2 segment performance, updated 2026 operating income down mid-single digits, cash flow guidance range, and deal targets (synergies, EPS accretion, leverage) plus raw-material cost headwinds and pass-through lag.
Market effects
Ingredient and food formulation peers may see read-through on tapioca cost inflation timing and the competitive impact of specialty solutions growth.
Mexico LATAM results highlight FX and demand sensitivity that could influence regional ingredient pricing and volume expectations.
Tate & Lyle acquisition targets (synergies, leverage) may affect broader consolidation expectations in global ingredients markets.
Counterpoint
Reaffirmed full-year EPS guidance could mask a longer-than-expected delay in tapioca cost pass-through, keeping margins under pressure even if volumes improve.
Key entities
- companyIngredion Incorporated
Reported Q2 2026 net sales of $1.85B, adjusted operating income of $258M, and reaffirmed full-year 2026 adjusted EPS guidance of $10.30 to $10.90 while updating operating income and cash flow expectations.
- companyTate & Lyle
Pending acquisition expected to add $2.7B revenue post-closing, with targeted $130M run-rate synergies by 2030 and >15% adjusted EPS accretion in the first full calendar year after close.
- facilityArgo facility
Primary North American production site; exited June at normal production rates after resolving refinery issues and an April 10 thermal event, but first-half operational headwinds reduced U.S./Canada operating income.
- companySanstar
Strategic partnership in India to expand pharmaceutical excipients capabilities and access large-scale manufacturing.
